Please login to the form below

Not currently logged in


This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

NICE gives nod to Gilead’s Zydelig

NICE gives nod to Gilead’s Zydelig

Zydelig (idelalisib) has been indicated in final draft guidance for patients whose leukaemia has come back less than 24 months after previous treatment. ... had agreed to provide idelalisib to the NHS at a reduced price in the initial submission. “

Latest news

More from news
Approximately 2 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...
2015/16 Pharmaceutical Titles
Browse our latest interactive Pharmaceutical and Healthcare catalogue...